In the latest issue of Transplant International, Magali Giral and colleagues studied the impact of switching from immediate- and prolonged-release tacrolimus to extended-release tacrolimus on tremor and quality of life in 221 kidney recipients. In this prospective, French multicentre study, the authors found a significant positive effect of the switch on tremor and SF-12 mental component score, and the physical component score and other neurological symptoms also tended to improve. The authors concluded that switching to extended-release tacrolimus was safe, increased the bioavailability of tacrolimus and concentration-to-dose ratio, and improved tremor and health-related quality of life.
